Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib versus dacarbazine in c-kit juxtamembrane-mutated unresectable or metastatic melanoma
2009-017918-69Phase 3Completed
- Sponsor
- AB Science
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Masitinib with Dacarbazine (2 arms). Primary endpoints: Tumor response and Disease progression. Started Feb 2010; status: completed.
02
Drugs
masitinibdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-017918-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017918-69.